文献速递眼底病与葡萄膜炎

阿柏西普与雷珠单抗治疗糖尿病黄斑水肿的三年治疗结局:来自Fight Retinal Blindness!登记研究的数据

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
PubMed 文献 · Retina · 2022-02-27

该回顾性分析基于Fight Retinal Blindness!登记研究,比较2013年1月1日至2017年12月31日期间初始接受玻璃体腔注射雷珠单抗0.5 mg或阿柏西普2 mg的初治糖尿病黄斑水肿眼。共纳入402例患者的534只眼(雷珠单抗组267只,阿柏西普组267只)。两组3年视力变化无临床差异,但阿柏西普组黄斑中心凹厚度降低更显著。

要点

  • 两组3年视力变化无临床差异:雷珠单抗组+1.3个字母,阿柏西普组+2.4个字母(P=0.001)。
  • 阿柏西普组黄斑中心凹厚度降低更显著:雷珠单抗组-87.8 µm vs 阿柏西普组-114.4 µm(P<0.01)。
  • 基线视力≤68个ETDRS字母时,阿柏西普组视力改善至18个月时更快,之后至36个月相似。

核心结论

  • 阿柏西普和雷珠单抗治疗糖尿病黄斑水肿3年均有效且安全。

研究设计与样本

  • 回顾性分析Fight Retinal Blindness!登记研究中2013年1月1日至2017年12月31日期间初始接受玻璃体腔注射雷珠单抗0.5 mg或阿柏西普2 mg的初治糖尿病黄斑水肿眼,共纳入402例患者的534只眼(雷珠单抗组267只,阿柏西普组267只)。

主要发现

  • 3年时调整后平均视力变化:雷珠单抗组+1.3个字母(95%CI -0.1至4.2),阿柏西普组+2.4个字母(95%CI -0.2至5.1),P=0.001,无临床差异。
  • 3年期间调整后平均黄斑中心凹厚度变化持续存在显著差异,阿柏西普组降低更多:雷珠单抗组-87.8 µm(95%CI -108.3至-67.4),阿柏西普组-114.4 µm(95%CI -134.4至-94.3),P<0.01。
  • 基线视力≤68个Early Treatment Diabetic Retinopathy Study字母时,阿柏西普组视力改善至治疗18个月时快于雷珠单抗组,之后至36个月相似;基线视力≥69个字母时无明显差异。
  • 严重不良事件发生率低。

关键数值与推荐

  • 雷珠单抗剂量0.5 mg,阿柏西普剂量2 mg,均为玻璃体腔注射。
  • 基线视力分层阈值:≤68个Early Treatment Diabetic Retinopathy Study字母为中度视力损害,≥69个字母为轻度视力损害。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Compare the 3-year outcomes of ranibizumab versus aflibercept in eyes with diabetic macular edema in daily practice. METHODS: This was a retrospective analysis of naive diabetic macular edema eyes starting intravitreal injections of ranibizumab (0.5 mg) or aflibercept (2 mg) from January 1, 2013 to December 31, 2017 that were collected in the Fight Retinal Blindness! Registry. RESULTS: We identified 534 eyes (ranibizumab-267 and aflibercept-267) of 402 patients. The adjusted mean (95% confidence interval) visual acuity change of +1.3 (-0.1 to 4.2) letters in the ranibizumab group and +2.4 (-0.2 to 5.1) letters (P = 0.001) in the aflibercept group at 3 years was not clinically different. However, the adjusted mean CST change seemed to remain significantly different throughout the 3-year period with higher reductions in favor of aflibercept (-87.8 [-108.3 to -67.4] µm for ranibizumab vs. -114.4 [-134.4 to -94.3] for aflibercept; P < 0.01). When baseline visual impairment was moderate (visual acuity ≤68 Early Treatment Diabetic Retinopathy Study letters), we found a faster improvement in visual acuity in eyes treated with aflibercept up until 18 months of treatment than eyes treated with ranibizumab, which then stayed similar until 36 months of treatment, whereas there was no apparent difference when baseline visual impairment was mild (visual acuity ≥69 Early Treatment Diabetic Retinopathy Study letters). The rate of serious adverse events was low. CONCLUSION: Aflibercept and ranibizumab were both effective and safe for diabetic macular edema over 3 years.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Gabrielle PH, Nguyen V, Creuzot-Garcher C, et al. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry. Retina. 2022. PMID: 35174799. doi:10.1097/IAE.0000000000003428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。